PL2820009T3 - Inhibitory kinaz serynowo/treoninowych - Google Patents

Inhibitory kinaz serynowo/treoninowych

Info

Publication number
PL2820009T3
PL2820009T3 PL13710222T PL13710222T PL2820009T3 PL 2820009 T3 PL2820009 T3 PL 2820009T3 PL 13710222 T PL13710222 T PL 13710222T PL 13710222 T PL13710222 T PL 13710222T PL 2820009 T3 PL2820009 T3 PL 2820009T3
Authority
PL
Poland
Prior art keywords
serine
kinase inhibitors
threonine kinase
threonine
inhibitors
Prior art date
Application number
PL13710222T
Other languages
English (en)
Inventor
James F. Blake
Mark Joseph Chicarelli
Rustam Ferdinand Garrey
John Gaudino
Jonas Grina
David A. Moreno
Peter J. Mohr
Li Ren
Jacob Schwarz
Huifen Chen
Kirk Robarge
Aihe Zhou
Original Assignee
Array Biopharma, Inc.
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma, Inc., Genentech, Inc. filed Critical Array Biopharma, Inc.
Publication of PL2820009T3 publication Critical patent/PL2820009T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13710222T 2012-03-01 2013-03-01 Inhibitory kinaz serynowo/treoninowych PL2820009T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605523P 2012-03-01 2012-03-01
EP13710222.4A EP2820009B1 (en) 2012-03-01 2013-03-01 Serine/threonine kinase inhibitors
PCT/US2013/028622 WO2013130976A1 (en) 2012-03-01 2013-03-01 Serine/threonine kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2820009T3 true PL2820009T3 (pl) 2018-09-28

Family

ID=47892024

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13710222T PL2820009T3 (pl) 2012-03-01 2013-03-01 Inhibitory kinaz serynowo/treoninowych
PL17207123T PL3321262T3 (pl) 2012-03-01 2013-03-01 Inhibitory kinaz serynowo/treoninowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17207123T PL3321262T3 (pl) 2012-03-01 2013-03-01 Inhibitory kinaz serynowo/treoninowych

Country Status (36)

Country Link
US (4) US8697715B2 (pl)
EP (2) EP3321262B1 (pl)
JP (2) JP6068515B2 (pl)
KR (1) KR102093526B1 (pl)
CN (2) CN104507926B (pl)
AR (2) AR090220A1 (pl)
AU (1) AU2013225737B2 (pl)
BR (1) BR112014021634B1 (pl)
CA (1) CA2866086C (pl)
CL (1) CL2014002301A1 (pl)
CO (1) CO7081155A2 (pl)
CR (1) CR20140413A (pl)
CY (1) CY1120172T1 (pl)
DK (2) DK3321262T3 (pl)
ES (2) ES2665073T3 (pl)
HR (2) HRP20180591T1 (pl)
HU (2) HUE037423T2 (pl)
IL (2) IL234376A (pl)
LT (2) LT2820009T (pl)
MX (1) MX354675B (pl)
MY (1) MY191936A (pl)
NO (1) NO2945854T3 (pl)
NZ (1) NZ700314A (pl)
PE (1) PE20150666A1 (pl)
PH (3) PH12015501654A1 (pl)
PL (2) PL2820009T3 (pl)
PT (2) PT3321262T (pl)
RS (2) RS57097B1 (pl)
RU (1) RU2650501C2 (pl)
SG (1) SG11201405356QA (pl)
SI (2) SI3321262T1 (pl)
SM (1) SMT201800282T1 (pl)
TW (1) TWI589569B (pl)
UA (1) UA116774C2 (pl)
WO (1) WO2013130976A1 (pl)
ZA (2) ZA201406688B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
CA2866086C (en) * 2012-03-01 2020-06-09 Genentech, Inc. Serine/threonine kinase inhibitors
CA2870049C (en) * 2012-05-03 2020-12-29 Charles Baker-Glenn Pyrazole aminopyrimidine derivatives as lrrk2 modulators
EP2888247B1 (en) 2012-08-27 2020-03-25 Array Biopharma, Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative diseases
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP2015533151A (ja) 2012-10-16 2015-11-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト セリン／スレオニンキナーゼ阻害剤
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
HUE039306T2 (hu) 2013-11-01 2018-12-28 Novartis Ag Kináz inhibitor aminoheteroaril-benzamidok
SG11201604573WA (en) 2013-12-06 2016-07-28 Genentech Inc Serine/threonine kinase inhibitors
BR112016015235A2 (pt) * 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
CN105980387B (zh) * 2013-12-30 2019-04-19 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
TWI678366B (zh) * 2014-04-09 2019-12-01 美商建南德克公司 製造藥物之方法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
EP3237420B1 (en) 2014-12-22 2018-09-26 Eli Lilly and Company Erk inhibitors
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
EP3303335B1 (en) * 2015-06-03 2021-07-28 JS Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
CN108617166B (zh) 2015-10-21 2022-05-17 大冢制药株式会社 蛋白激酶抑制剂苯并内酰胺化合物
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
MX376639B (es) 2015-11-09 2025-03-07 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
CA3018406A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
SG11201810579YA (en) 2016-06-16 2018-12-28 Denali Therapeutics Inc Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN111032656B (zh) * 2017-08-22 2022-12-02 捷思英达医药技术（上海）有限公司 杂环化合物激酶抑制剂及其药物组合物和应用
JP7199737B2 (ja) * 2017-08-23 2023-01-06 スプリント バイオサイエンス アクティエボラーグ ピリジルピリドン化合物
AU2018329925B2 (en) 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
CR20200211A (es) 2017-11-24 2020-06-19 Novartis Ag Derivados de piridinona y uso como inhibidores selectivos de alk-2
ES2936627T3 (es) * 2018-02-08 2023-03-21 Zhangzhou Pien Tze Huang Pharm Compuesto de pirazina-2(1H)-cetona como inhibidor de FGFR
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019223632A1 (en) * 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
TW202102511A (zh) * 2019-03-28 2021-01-16 大陸商江蘇恆瑞醫藥股份有限公司 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用
CN113784970B (zh) * 2019-05-15 2022-11-29 南京明德新药研发有限公司 Erk抑制剂及其应用
KR20210015730A (ko) 2019-08-02 2021-02-10 웰마커바이오 주식회사 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물
WO2022100586A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用
WO2025067459A2 (en) 2023-09-29 2025-04-03 D3 Bio (Wuxi) Co., Ltd. Therapies for the treatment of cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
ATE325113T1 (de) 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
WO2001062233A2 (en) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
NZ521633A (en) 2000-04-26 2005-01-28 Eisai Co Ltd Use of an adenosine A2 or A2b recpetor antagonist for promoting bowel movement
EP1280771B1 (de) 2000-05-02 2004-10-13 Tietze, Lutz F., Prof. Dr. Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo 3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo f]chinolin-derivaten für eine selektive krebstherapie
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (pl) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
WO2003057689A1 (en) * 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
EA008008B1 (ru) * 2002-02-14 2007-02-27 Фармация Корпорейшн Замещённые пиридиноны в качестве модуляторов мар-киназы р38
MXPA04011470A (es) * 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7208498B2 (en) 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
NL1026826C2 (nl) * 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
JP2007532669A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリミジン
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP1786781A2 (en) 2004-08-27 2007-05-23 GPC Biotech AG Pyrimidine derivatives
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CN101415674A (zh) 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
MX2009001913A (es) 2006-08-23 2009-03-06 Pfizer Prod Inc Compuestos de pirimidona como inhibidores de gsk-3.
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US20100048597A1 (en) 2006-12-22 2010-02-25 Novartis Ag Organic Compounds and Their Uses
ATE467630T1 (de) 2007-02-01 2010-05-15 Tibotec Pharm Ltd Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv
AU2008258508A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009032861A1 (en) 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
EP2205086B1 (en) 2007-11-06 2013-08-14 E. I. du Pont de Nemours and Company Fungicidal heterocyclic amines
CA2714479A1 (en) 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
KR101955914B1 (ko) 2008-06-27 2019-03-11 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
CA2729327C (en) 2008-06-27 2016-10-11 Xenon Pharmaceuticals Inc. Heterocyclic derivatives that modulate the activity of stearoyl-coa desaturase
PT2370413E (pt) * 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
DE102009051799B4 (de) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
JPWO2012020786A1 (ja) * 2010-08-11 2013-10-28 日本新薬株式会社 医薬組成物
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
CA2866086C (en) 2012-03-01 2020-06-09 Genentech, Inc. Serine/threonine kinase inhibitors
EP2888247B1 (en) 2012-08-27 2020-03-25 Array Biopharma, Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative diseases
KR102244553B1 (ko) 2013-08-23 2021-04-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 용량 소자 및 반도체 장치
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CN105980387B (zh) * 2013-12-30 2019-04-19 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
BR112016015235A2 (pt) * 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
TWI678366B (zh) * 2014-04-09 2019-12-01 美商建南德克公司 製造藥物之方法

Also Published As

Publication number Publication date
JP2015508828A (ja) 2015-03-23
MX354675B (es) 2018-03-15
US9259470B2 (en) 2016-02-16
PH12015501653A1 (en) 2017-04-10
LT2820009T (lt) 2018-05-10
CN106349217B (zh) 2020-08-28
MY191936A (en) 2022-07-19
PH12014501947B1 (en) 2014-11-24
AU2013225737B2 (en) 2018-03-01
AR121879A2 (es) 2022-07-20
RS57097B1 (sr) 2018-06-29
US20160122316A1 (en) 2016-05-05
CL2014002301A1 (es) 2015-05-08
HUE053994T2 (hu) 2021-08-30
CA2866086A1 (en) 2013-09-06
LT3321262T (lt) 2021-06-10
PH12015501653B1 (en) 2018-01-17
HRP20180591T1 (hr) 2018-05-18
SG11201405356QA (en) 2014-11-27
CA2866086C (en) 2020-06-09
PH12015501654B1 (en) 2017-04-10
HK1204323A1 (zh) 2015-11-13
KR20140138820A (ko) 2014-12-04
RU2014139601A (ru) 2016-04-20
HUE037423T2 (hu) 2018-08-28
ES2857649T3 (es) 2021-09-29
PL3321262T3 (pl) 2021-06-28
ZA201406688B (en) 2017-08-30
SI2820009T1 (en) 2018-05-31
DK2820009T3 (en) 2018-04-16
AR090220A1 (es) 2014-10-29
BR112014021634B1 (pt) 2022-09-27
US8697715B2 (en) 2014-04-15
TWI589569B (zh) 2017-07-01
EP2820009A1 (en) 2015-01-07
JP2016027053A (ja) 2016-02-18
ZA201508847B (en) 2023-01-25
PH12014501947A1 (en) 2014-11-24
US9708290B2 (en) 2017-07-18
RU2650501C2 (ru) 2018-04-16
EP3321262A1 (en) 2018-05-16
NO2945854T3 (pl) 2018-07-21
HK1254429A1 (en) 2019-07-19
UA116774C2 (uk) 2018-05-10
PT2820009T (pt) 2018-04-12
CR20140413A (es) 2014-11-05
US10519126B2 (en) 2019-12-31
CN106349217A (zh) 2017-01-25
WO2013130976A1 (en) 2013-09-06
EP2820009B1 (en) 2018-01-31
EP3321262B1 (en) 2021-01-13
KR102093526B1 (ko) 2020-03-25
PE20150666A1 (es) 2015-05-06
US20140249127A1 (en) 2014-09-04
JP6068515B2 (ja) 2017-01-25
IL244276B (en) 2020-01-30
TW201339146A (zh) 2013-10-01
US20130252934A1 (en) 2013-09-26
CN104507926A (zh) 2015-04-08
ES2665073T3 (es) 2018-04-24
SMT201800282T1 (it) 2018-07-17
DK3321262T3 (da) 2021-01-25
IL234376A (en) 2016-10-31
SI3321262T1 (sl) 2021-04-30
RS61500B1 (sr) 2021-03-31
CN104507926B (zh) 2016-08-31
CY1120172T1 (el) 2018-12-12
MX2014010432A (es) 2015-02-04
HRP20210482T1 (hr) 2021-05-14
US20180127393A1 (en) 2018-05-10
CO7081155A2 (es) 2014-10-10
HK1206011A1 (en) 2015-12-31
NZ700314A (en) 2016-08-26
BR112014021634A8 (pt) 2018-01-30
IL244276A0 (en) 2016-04-21
PH12015501654A1 (en) 2017-04-10
PT3321262T (pt) 2021-03-04

Similar Documents

Publication Publication Date Title
ZA201508847B (en) Serine/threonine kinase inhibitors
IL261282A (en) Furinone compounds as kinase inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HUE048834T2 (hu) Kináz inhibitorok
ZA201404156B (en) Kinase inhibitors
IL229028A0 (en) Kinase inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
PL2634185T3 (pl) Inhibitory kinazy TYK2
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
GB201211310D0 (en) CSF-1R kinase inhibitors
ZA201604461B (en) Serine/threonine kinase inhibitors
ZA201404157B (en) Kinase inhibitors
PT2912021T (pt) Inibidores de agrecanase
EP2847186A4 (en) SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER
EP2900243A4 (en) BICYCLIC OXA LACTAM KINASE HEMMER
HK1192543A (en) Serine/threonine kinase inhibitors